Evidence map›Paper›PMID 35727057›Full record

ArticleAntimicrobial agents and chemotherapy2022

Parasite Viability as a Measure of

Georges F R Radohery, Annabelle Walz, Christin Gumpp, Mohammed H Cherkaoui-Rbati, Nathalie Gobeau, Jeremy Gower, Miles P Davenport, Matthias Rottmann, James S McCarthy, Jörg J Möhrle and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. IncompleteFrontiers in cellular and infection microbiology · 2024
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Georges F R Radohery *Kirby Institute, University of New South Wales, Kensington, New South Wales, Australia.
Annabelle Walz *Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland.
Christin GumppDepartment of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland.
Mohammed H Cherkaoui-RbatiMedicines for Malaria Venturegrid.452605.0, Geneva, Switzerland.
Nathalie GobeauMedicines for Malaria Venturegrid.452605.0, Geneva, Switzerland.
Jeremy GowerQIMR Berghofer Medical Research Institutegrid.1049.c, Brisbane, Queensland, Australia.
Miles P DavenportKirby Institute, University of New South Wales, Kensington, New South Wales, Australia.
Matthias RottmannDepartment of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland.
James S McCarthyQIMR Berghofer Medical Research Institutegrid.1049.c, Brisbane, Queensland, Australia.ORCID 0000-0001-6596-9718
Jörg J MöhrleMedicines for Malaria Venturegrid.452605.0, Geneva, Switzerland.ORCID 0000-0002-0769-9649
Maria RebeloQIMR Berghofer Medical Research Institutegrid.1049.c, Brisbane, Queensland, Australia.
Claudia Demarta-GatsiMedicines for Malaria Venturegrid.452605.0, Geneva, Switzerland.
David S KhouryKirby Institute, University of New South Wales, Kensington, New South Wales, Australia.ORCID 0000-0002-2663-1551
Medicines for Malaria Venture · CHQIMR Berghofer Medical Research Institute · AUSwiss Tropical and Public Health Institute · CHUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rate at which parasitemia declines in a host after treatment with an antimalarial drug is a major metric for assessment of antimalarial drug activity in preclinical models and in early clinical trials. However, this metric does not distinguish between viable and nonviable parasites. Thus, enumeration of parasites may result in underestimation of drug activity for some compounds, potentially confounding its use as a metric for assessing antimalarial activity

Indexed as

AntimalarialsArtemisininsMalaria, FalciparumParasitesAnimalsArtesunateAustraliaHumansMiceParasitemiaPlasmodium falciparumAntimalarialsArtemisininsArtesunateantimicrobial activityartesunateclinical trialsdrug activitymalariaPlasmodium falciparumpreclinical drug studiesviability

Identifiers

PMID35727057
PMCPMC9295577
OpenAlexW4283212159

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.